Trial Profile
A Phase I/II Study Evaluating the Feasibility and Safety of Neoadjuvant Gemcitabine/Nab-paclitaxel (GA) and Concurrent Gemcitabine and Radiation Therapy Followed By Pancreatic Resection and Major Arterial Resection for Adenocarcinoma of the Pancreas (ARCAP) in Patients With Advanced Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 08 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2024.
- 08 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 25 Jan 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2023.